Neoplasms

All Conditions

Symptoms and General Pathology

Skin and Connective Tissue Diseases

Rare Diseases

Sarcoma

Liposarcoma

Neoplastic Cells, Circulating

Leiomyosarcoma

Sarcoma, Synovial

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Neoplasm Metastasis

Neoplastic Processes

Neoplasms, Adipose Tissue

Neoplasms, Connective Tissue

Soft Tissue Sarcoma

Synovial Sarcoma

Ludmilla Chinen, PhD

The sarcomas represent 1% of all cancers in adults, 8% in adolescents and young people, and 10% in children. Even though it is a rare cancer, it contributes to a significant loss of years of life in comparison with other types of cancer, due the fact that it affects children and young people. The diagnosis and treatment are difficult, considering the diversity and rarity of this disease. In addition, on average, more than 50% of patients with high-grade sarcoma present tumor relapse and distant recurrence is considered the main cause of death. The presence of Circulating Tumor Cells (CTCs) in the blood of patients with sarcoma may be an early marker of tumor invasion, because it is known that the CTCs circulate in the blood for months or years before the development of metastases. The CTCs can be used to monitor the response of the tumor to treatment, in order to match time, dose, and type of therapy.

Objectives: collect blood from patients with different types of sarcoma (leiomyosarcoma, synovial sarcoma, pleomorphic sarcoma and liposarcoma) in order to isolate and quantify CTCs. The investigators also have an intention to identify genes of resistance to treatment in these cells.

Methodology: This is a prospective study, to be made by whole blood collection from 40 patients with different types of sarcomas (leiomyosarcoma, pleomorphic sarcoma, synovial sarcoma and liposarcoma). The collections will be made in three different moments: before the beginning of the treatment, during and at the end of this (8 mL). Blood samples will be processed and filtered on ISET system for the isolation and quantification of CTCs. Later, it will be performed immunocytochemistry (ICQ) single and/or double staining for protein assessment. The following proteins will be assessed: CD45, MRP1, MRP2 and MRP7.

Expected Results: The investigators hope that this study can show if the CTCs can be used as "liquid biopsy" in patients with leiomyosarcoma, synovium and pleomorphic sarcoma and liposarcoma.

Detection of Circulating Tumor Cells in Patients With Sarcomas

Detection of Circulating Tumor Cells in Patients With Metastatic Sarcomas

time to first progression until the second one

AC Camargo Cancer Center

Researcher

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Infections

Immune System Diseases

Uterine Cervical Neoplasms

Acquired Immunodeficiency Syndrome

HIV Infections

HIV Seropositivity

Uterine Cervical Dysplasia

Uterine Cervical Diseases

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Central Nervous System Depressants

All Drugs and Chemicals

Anti-Arrhythmia Agents

Channel Blockers

Anti-Infective Agents

Antineoplastic Agents

Micronutrients

Coagulants

Vitamins

Anesthetics

Lidocaine

Anesthetics, Local

Acetic Acid

Retinol acetate

Iodine

Lugol's solution

Cadexomer iodine

those who serologically tested positive for HIV

those who serologically tested negative for HIV

those with no available serological test for HIV

Cervical specimen obtained using speculum examination and cervical collection bush.

Screening

Vaginal speculum examination followed by application of 2% acetic acid and lugol's iodine with inspection with colposcope and punch biopsies taken of abnormal areas.

Colposcopy

The above (see colposcopy) is followed by local anaesthetic with two dentist's ampoules of lignocaine and large loop excision using coagulation of the abnormal area (usually 2 x 3 x 1 cm).

LLETZ

Greta Dreyer, PhD

Cathy Visser, MSc

Leon C Snyman, MMedO&G;FCOG

Greta D Dreyer, PhD

Nearly 8 000 new cervical cancer cases are diagnosed in South Africa per year; many are still undiagnosed and about 50% of diagnosed cases succumb per year. Although the current prevalence of pre-cancer cervical disease is largely unknown, data from local studies suggest regional differences and an increase in the prevalence of cytological abnormalities when compared with historical data. Low frequency in cytology screening is the primary factor attributable to development of invasive cervical cancer and almost one-third of all cervical cancer patients had previous negative cytology. Due to the low sensitivity of cytology it can be assumed that the true prevalence of pre-cancer disease is underestimated by all available data. One round of optimal cervical cytology will detect around 50% of existing pre-cancer cervical disease as identified and proven using colposcopy and directed biopsy. It is now widely accepted that primary screening with a human papilloma virus (HPV) test can improve the sensitivity of screening and that even a single round of HPV screening can rapidly reduce the incidence of invasive cervical cancer and related mortality within a few years.

South Africa has a high prevalence of HIV infection and a delay in or failure to initiate antiretroviral therapy (ART). These facts, together with the largely unscreened status of the female population and the high incidence of cervical cancer all suggest that HPV infection and precursors to cervical cancer are both unusually common among South African women. Accurate current knowledge of the performance of newer generation HPV based screening tests in HIV-infected and general female population are essential for cost-analysis and planning for national prevention and screening programs. This study will aim to demonstrate the feasibility and efficacy of new generation HPV deoxyribonucleic acid (DNA) based screening assays in a South African setting.

The investigators hypothesize that HPV testing followed by normal and special cytology tests will be a successful screening model for a South African population.

Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.

Primary HPV Screening as an Indicator of Cervical Pre-invasive and Invasive Neoplasia in HIV-positive and -Negative Southern African Women

University of Stellenbosch

University of Pretoria

Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Detection of Circulating Tumor Cells in Patients With Sarcomas	NCT02983539	Leiomyosarcoma Pleomorphic Lip... Synovial Sarcom... Liposarcoma		18 Years - 70 Years	AC Camargo Cancer Center
Detection of Circulating Tumor Cells in Patients With Sarcomas	NCT02983539	Leiomyosarcoma Pleomorphic Lip... Synovial Sarcom... Liposarcoma		18 Years - 70 Years	AC Camargo Cancer Center
Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.	NCT02956031	Cervical Cancer High Grade Sil CIN2	Screening Colposcopy LLETZ	25 Years - 75 Years	University of Pretoria

Spots Global Cancer Trial Database for immunocytochemistry